Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut [Yahoo! Finance]
Voyager Therapeutics, Inc. (VYGR)
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.voyagertherapeutics.com
Company Research
Source: Yahoo! Finance
antibody with a multiple-ascending-dose study and expected tau PET imaging readout by year-end, plus an siRNA-based tau knockdown gene therapy with a mid-year readout and reported cortical knockdown roughly in the 50%–75% range. Voyager plans to deploy its newly discovered BBB-penetrant capsids clinically in 2026 (IND for the tau knockdown targeted for Q2, clinic entry in H2) and aims to show broad brain gene expression and fluid biomarker signals, while also advancing a shuttle platform that identified receptors including ALPL (NHP studies and safety assessments underway with hypophosphatasia risks noted). Business strategy emphasizes partnerships — notably multiple programs with Neurocrine, Novartis and AstraZeneca — where partners advance programs to IND/Phase 1 while Voyager retains potential U.S. opt-in rights (e.g., 40% for Friedreich's ataxia, 50% for GBA1) plus milestones and royalties. Interested in Voyager Therapeutics, Inc.? Here are five stocks we like better. Voya
Show less
Read more
Impact Snapshot
Event Time:
VYGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYGR alerts
High impacting Voyager Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VYGR
News
- Voyager Therapeutics (VYGR) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript [Seeking Alpha]Seeking Alpha
- Voyager Therapeutics (VYGR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Voyager Therapeutics (VYGR) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VYGR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "selMarketBeat
- Does Voyager Therapeutics' (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? [Yahoo! Finance]Yahoo! Finance
VYGR
Earnings
- 3/9/26 - Beat
VYGR
Analyst Actions
- 3/17/26 - HC Wainwright
VYGR
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/9/26 - Form 8-K
- 3/9/26 - Form 10-K
- VYGR's page on the SEC website